Although CD8+ T cells are well-documented for their direct tumor-killing abilities (33, 36, 37), our results suggest that NSG2 may amplify tumor immunogenicity, leading to increased CD4+ and CD8+ T cells populations. Here, CD4 is linked to neoplasm.